Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Interoception in Adolescents With Restrictive Eating Disorders and Autism Spectrum Disorder (INT-REDS-ASD)

16 de noviembre de 2026 actualizado por: Fondazione IRCCS San Gerardo dei Tintori

"Tuning Into My Body": A Study of Interoception in Adolescents With Restrictive Eating Disorders and Comorbid Autism Spectrum Disorder

The goal of this observational study is to describe interoception (the ability to sense signals from inside the body, such as heartbeat, hunger, and fullness) in three groups of adolescents aged 13 to 18: those with restrictive eating disorders (REDs), those with autism spectrum disorder (ASD), and those with both REDs and ASD.

The main questions it aims to answer are:

  • What is the level of interoceptive accuracy (how precisely participants perceive their own heartbeat), as measured by the Heartbeat Counting Task (HCT), in each of the three groups?
  • What is the level of interoceptive sensitivity (how participants self-report their awareness of body signals), as measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2), in each of the three groups?

In each group, researchers will also explore whether interoceptive accuracy and sensitivity are associated with:

  • socio-demographic and clinical characteristics (gender, age, body mass index, illness duration, and IQ)
  • psychological characteristics, including alexithymia (difficulty identifying and describing emotions), eating disorder symptoms and their severity, general psychological distress, and emotion dysregulation

Participants will:

  • Complete the Heartbeat Counting Task (HCT), in which they silently count their own heartbeats
  • Fill in the MAIA-2 questionnaire about body awareness, along with other questionnaires about eating behaviors, emotions, and general well-being

All information will be collected during the standard clinical assessment, with no extra visits or procedures.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

Restrictive eating disorders (REDs), including anorexia nervosa and avoidant/restrictive food intake disorder, and autism spectrum disorder (ASD) frequently co-occur, and their overlap is associated with more severe psychopathology. Interoception, the process by which the nervous system senses, interprets, and integrates signals from inside the body, has been found to be impaired in both conditions, but little is known about interoception in adolescents with REDs and comorbid ASD.

Following the multidimensional model proposed by Garfinkel et al. (2015), this multicenter prospective observational study will assess two dimensions of interoception: interoceptive accuracy (objective performance in detecting internal body signals) and interoceptive sensitivity (self-reported perception of body signals). Three clinical groups of adolescents will be described: REDs only, ASD only, and REDs with comorbid ASD.

No study-specific procedures are planned. During the standard psychodiagnostic assessment, participants complete a modified Heartbeat Counting Task (HCT) with a time estimation control task, the MAIA-2, and other self-report questionnaires (TAS-20, EDI-3, SCL-90-R, AQ, EQ, DERS-IT-SF), and undergo cognitive assessment (WISC-V). Socio-demographic and clinical data are also collected. Interoceptive accuracy and sensitivity will be described in each group with measures of location and variability and 95% confidence intervals, and their associations with socio-demographic, clinical, and psychological variables will be explored.

Tipo de estudio

De observación

Inscripción (Estimado)

180

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Bo
      • Bologna, Bo, Italia, 40138
        • IRCCS Istituto delle Scienze Neurologiche di Bologna
        • Contacto:
    • MB
    • PD
      • Padova, PD, Italia, 35128
        • Azienda Ospedale-Università Padova
        • Contacto:
    • PV
      • Pavia, PV, Italia, 27100
        • Fondazione IRCCS Mondino
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

13 años a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adolescents aged 13 to 18 years with a confirmed DSM-5-TR diagnosis of restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder), autism spectrum disorder (level 1), or restrictive eating disorder with comorbid autism spectrum disorder (level 1), recruited during their standard psychodiagnostic assessment among patients under the care of four Italian child and adolescent neuropsychiatry centers: Fondazione IRCCS San Gerardo dei Tintori (Monza, coordinating center), IRCCS Istituto delle Scienze Neurologiche di Bologna, Azienda Ospedale-Università Padova, and Fondazione IRCCS Mondino (Pavia).

Descripción

Inclusion Criteria:

  • Confirmed diagnosis, according to DSM-5-TR criteria, of one of the following: restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder); autism spectrum disorder, level 1; or restrictive eating disorder with comorbid autism spectrum disorder, level 1
  • Age between 13 and 18 years at diagnosis
  • Written informed consent freely given and obtained before the start of the study from the participant and/or parent or legal guardian

Exclusion Criteria:

  • Intellectual disability (IQ < 70)
  • Insufficient understanding of the Italian language
  • Past or current psychotic disorders

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Restrictive Eating Disorders (REDs)

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) according to DSM-5-TR criteria, without autism spectrum disorder.

Autism Spectrum Disorder (ASD)

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of autism spectrum disorder, level 1, according to DSM-5-TR criteria, without a restrictive eating disorder.

REDs With Comorbid ASD

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) and comorbid autism spectrum disorder, level 1, according to DSM-5-TR criteria.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Interoceptive Accuracy Measured by the Heartbeat Counting Task (HCT)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Interoceptive accuracy assessed with a modified version of the Heartbeat Counting Task. Participants silently count their heartbeats, without taking their pulse, during four randomized time intervals while heart rate is recorded with a finger pulse oximeter. The accuracy score is calculated as the mean across intervals of [1 - |(recorded heartbeats - counted heartbeats) / recorded heartbeats|] × 100. Scores range from 0 to 100, with higher scores indicating greater interoceptive accuracy.

At enrollment, during the standard diagnostic assessment
Interoceptive Sensibility Measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Self-reported interoceptive sensibility assessed with the MAIA-2, a 37-item questionnaire rated on a 6-point scale (0-5). Mean scores are calculated for each of the 8 subscales (Noticing, Not-Distracting, Not-Worrying, Attention Regulation, Emotional Awareness, Self-Regulation, Body Listening, Trusting) and range from 0 to 5. Higher scores indicate greater interoceptive sensibility.

At enrollment, during the standard diagnostic assessment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlations Between Interoceptive Measures and Sociodemographic Variables
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with gender (number of participants per category) and age (years), collected from clinical records. Analyzed in each clinical group.

At enrollment, during the standard diagnostic assessment
Correlations Between Interoceptive Measures and Clinical Variables
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with body mass index (BMI, kg/m²), duration of illness (months), and Full Scale IQ measured by the WISC-V (standard score, mean 100, SD 15), collected from clinical records. Analyzed in each clinical group.

At enrollment, during the standard diagnostic assessment
Alexithymia Measured by the Toronto Alexithymia Scale (TAS-20)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Alexithymia assessed with the TAS-20, a 20-item self-report questionnaire rated on a 5-point Likert scale. Total score ranges from 20 to 100 (subscales: Difficulty Identifying Feelings, Difficulty Describing Feelings, Externally Oriented Thinking); higher scores indicate greater alexithymia. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
Eating Disorder Symptom Severity Measured by the Eating Disorder Inventory-3 (EDI-3)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Eating disorder symptoms assessed with the EDI-3, a 91-item self-report questionnaire comprising 12 primary scales and 6 composite scales, including the Eating Disorder Risk Composite. Raw scores are converted to T-scores; higher scores indicate greater symptom severity. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
General Psychopathology Measured by the Symptom Checklist-90-Revised (SCL-90-R)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

General psychopathology assessed with the SCL-90-R, a 90-item self-report questionnaire rated from 0 to 4, covering 9 symptom dimensions. The Global Severity Index (GSI) ranges from 0 to 4; higher scores indicate greater psychological distress. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
Emotion Dysregulation Measured by the Difficulties in Emotion Regulation Scale - Italian Short Form (DERS-IT-SF)
Periodo de tiempo: At enrollment, during the standard diagnostic assessment

Emotion dysregulation assessed with the DERS-IT-SF, a self-report questionnaire rated on a 5-point Likert scale. Higher total and subscale scores indicate greater difficulties in emotion regulation. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Renata Nacinovich, Fondazione IRCCS San Gerardo dei Tintori

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

6 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • INT-REDS-ASD
  • 7306 (Otro identificador: Comitato Etico Territoriale Lombardia 3 (Territorial Ethics Committee Lombardy 3))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

A decision on sharing individual participant data has not yet been made. Any future sharing of pseudonymized data would take place only in accordance with the informed consent, the EU General Data Protection Regulation (GDPR), and applicable Italian data protection law.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .